Oct 01, 2019 11:46 JST

Source: Eisai

Eisai: Final Study Results Evaluating LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination Treatment in Advanced Endometrial Cancer Presented at ESMO 2019 Congress


TOKYO, Oct 01, 2019 - (JCN Newswire) - Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. (NYSE: MRK), known as MSD outside the United States and Canada, announced final results from the full endometrial cancer cohort of KEYNOTE- 146/Study 111 evaluating LENVIMA, an orally available kinase inhibitor discovered by Eisai , plus KEYTRUDA, Merck & Co., Inc., Kenilworth, N.J., U.S.A.'s anti-PD-1 therapy. The findings were presented in a proffered paper presentation at the European Society for Medical Oncology (ESMO) 2019 Congress (Abstract #994O).

For the full report, visit https://www.eisai.com/news/2019/pdf/enews201977pdf.pdf.


About Eisai
Eisai Co., Ltd. defines our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products to address unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology. As a global pharmaceutical company, our mission extends to patients around the world through working with key stakeholders to improve access to medicines in developing and emerging countries.

For more information about Eisai Co., Ltd., please visit https://www.eisai.com


Contact:
Eisai Co., Ltd. 
Media Relations 
+81-(0)3-3817-5120

Merck & Co., Inc., Kenilworth, N.J., U.S.A. 
Media Relations 
Pamela Eisele: (267) 305-3558 
Kristen Drake: (908) 334-4688
Source: Eisai
Sectors: BioTech

Copyright ©2020 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


Eisai Receives Positive Opinion from EMA's CHMP on Use of Antiepileptic Agent Fycompa in Pediatric Patients
September 23 2020 08:24 JST
 
Eisai and Merck Present First-Time Data From Two Studies Evaluating KEYTRUDA (pembrolizumab) Plus LENVIMA (lenvatinib) in Seven Different Tumor Types at ESMO Virtual Congress 2020
September 23 2020 08:10 JST
 
Eisai Presents Latest Data of Phase I Clinical Trial on Liposomal Formulation of Anti-Cancer Agent Halaven (Eribulin) at ESMO Virtual Congress 2020
September 18 2020 10:29 JST
 
Eisai Establishes Pharma Sales Subsidiary in Vietnam
September 17 2020 08:59 JST
 
Eisai to Present Abstracts on Oncology Products and Pipeline at ESMO Virtual Congress 2020
September 11 2020 09:41 JST
 
Eisai to Take over Manufacturing and Marketing Approval for Equfina 50mg Tablets (Safinamide Mesilate) in Japan from Meiji Seika Pharma
September 07 2020 08:02 JST
 
Eisai to Launch Sahne Medical Spray and Sahne Medical Cream
August 25 2020 11:55 JST
 
Eisai to Present Latest Data of Lemborexant at 34th Annual Sleep Meeting (SLEEP2020)
August 25 2020 09:30 JST
 
Eisai: Application for Additional Indication of Anti Cancer Agent Lenvima for Unresectable Thymic Carcinoma Submitted in Japan
July 31 2020 08:31 JST
 
Eisai to Present Latest Data on Pipeline Assets in the Area of Alzheimer's Disease and Dementia at the Alzheimer's Association International Conference (AAIC) 2020
July 22 2020 16:04 JST
 
More Press release >>

Latest Press Release


More Latest Release >>